# Sigrid V Carlsson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 137 papers | 7,327 citations | 101384 36 h-index | 56606 83 g-index |
| 143 all docs | 143 docs citations | 143 times ranked | 6931 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035. | 6.3 | 1,261 |
| 2 | Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine, 2012, 366, 981-990. | 13.9 | 1,105 |
| 3 | Mortality results from the GÃ¶teborg randomised population-based prostate-cancer screening trial. Lancet Oncology, The, 2010, 11, 725-732. | 5.1 | 843 |
| 4 | Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605. | 13.9 | 364 |
| 5 | A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51. | 0.9 | 359 |
| 6 | Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). European Urology, 2012, 62, 745-752. | 0.9 | 216 |
| 7 | The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nature Reviews Urology, 2017, 14, 26-37. | 1.9 | 158 |
| 8 | Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162. | 0.6 | 137 |
| 9 | Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. European Urology, 2015, 67, 619-626. | 0.9 | 129 |
| 10 | Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review. Journal of Clinical Oncology, 2012, 30, 2581-2584. | 0.8 | 114 |
| 11 | Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890. | 0.9 | 111 |
| 12 | Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Translational Andrology and Urology, 2018, 7, 83-97. | 0.6 | 99 |
| 13 | Risk stratification in prostate cancer screening. Nature Reviews Urology, 2013, 10, 38-48. | 1.9 | 97 |
| 14 | Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. European Urology, 2018, 74, 261-280. | 0.9 | 82 |
| 15 | Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ, The, 2014, 348, g2296-g2296. | 3.0 | 79 |
| 16 | Screening for Prostate Cancer. Medical Clinics of North America, 2020, 104, 1051-1062. | 1.1 | 79 |
| 17 | Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam. European Urology, 2013, 64, 693-699. | 0.9 | 78 |
| 18 | Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2705-2711. | 0.8 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the GÃ¶teborg Randomised Screening Trial. European Urology, 2016, 70, 566-573. | 0.9 | 65 |
| 20 | Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. European Urology Oncology, 2018, 1, 353-360. | 2.6 | 61 |
| 21 | Populationâ€based study of longâ€term functional outcomes after prostate cancer treatment. BJU International, 2016, 117, E36-45. | 1.3 | 58 |
| 22 | Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127. | 0.2 | 58 |
| 23 | Risk of suicide in men with low-risk prostate cancer. European Journal of Cancer, 2013, 49, 1588-1599. | 1.3 | 55 |
| 24 | Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) â€“ Results from a prospective, population-based, randomised study. European Journal of Cancer, 2007, 43, 2109-2116. | 1.3 | 54 |
| 25 | Eighteen-year follow-up of the GÃ¶teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scandinavian Journal of Urology, 2018, 52, 27-37. | 0.6 | 53 |
| 26 | Validation of the Swedish M. D. Anderson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer and Neurologic Swallowing Disturbances. Dysphagia, 2012, 27, 361-369. | 1.0 | 51 |
| 27 | Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. European Urology, 2020, 78, 304-306. | 0.9 | 44 |
| 28 | Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Thrombosis and Haemostasis, 2013, 110, 484-492. | 1.8 | 43 |
| 29 | Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407. | 0.9 | 43 |
| 30 | Screening for Prostate Cancer Starting at Age 50â€“54 Years. A Population-based Cohort Study. European Urology, 2017, 71, 46-52. | 0.9 | 42 |
| 31 | Radical retropubic prostatectomy: A review of outcomes and side-effects. Acta OncolÃ³gica, 2011, 50, 92-97. | 0.8 | 41 |
| 32 | Development and validation of the Gothenburg Trismus Questionnaire (GTQ). Oral Oncology, 2012, 48, 730-736. | 0.8 | 41 |
| 33 | Active surveillance for prostate cancer. International Journal of Urology, 2016, 23, 211-218. | 0.5 | 40 |
| 34 | Pathological Features of Lymph Node Metastasis for Predicting Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2013, 189, 1314-1319. | 0.2 | 39 |
| 35 | Oncological and functional outcomes 1 year after radical prostatectomy for veryâ€lowâ€risk prostate cancer: results from the prospective <scp>LAPPRO</scp> trial. BJU International, 2016, 118, 205-212. | 1.3 | 38 |
| 36 | Overdetection in screening for prostate cancer. Current Opinion in Urology, 2014, 24, 256-263. | 0.9 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence. Journal of the National Cancer Institute, 2014, 106, dju007-dju007. | 3.0 | 36 |
| 38 | A positive family history as a risk factor for prostate cancer in a populationâ€based study with organised prostateâ€specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (<scp>ERSPC</scp>, Aarau). BJU International, 2016, 117, 576-583. | 1.3 | 36 |
| 39 | Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clinical Cancer Research, 2016, 22, 243-249. | 3.2 | 35 |
| 40 | The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The GÃ¶teborg randomised population-based prostate cancer screening trial. European Journal of Cancer, 2011, 47, 545-553. | 1.3 | 34 |
| 41 | Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years. JAMA Network Open, 2020, 3, e1919284. | 2.8 | 33 |
| 42 | Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. Scandinavian Journal of Urology, 2019, 53, 304-311. | 0.6 | 31 |
| 43 | No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU International, 2011, 107, 1912-1917. | 1.3 | 29 |
| 44 | Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. Nature Reviews Urology, 2021, 18, 259-281. | 1.9 | 29 |
| 45 | Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate, 2019, 79, 1079-1089. | 1.2 | 28 |
| 46 | Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121. | 0.2 | 28 |
| 47 | Towards an Optimal Interval for Prostate Cancer Screening. European Urology, 2012, 61, 171-176. | 0.9 | 27 |
| 48 | The GÃ–TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scandinavian Journal of Urology, 2021, 55, 116-124. | 0.6 | 27 |
| 49 | Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence. Journal of the National Cancer Institute, 2014, 106, dju010-dju010. | 3.0 | 25 |
| 50 | Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. BJU International, 2021, 127, 361-368. | 1.3 | 24 |
| 51 | Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393. | 2.0 | 23 |
| 52 | Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Current Opinion in Urology, 2017, 27, 198-204. | 0.9 | 23 |
| 53 | Lifetime Benefits and Harms of Prostate-Specific Antigenâ€“BasedÂRisk-Stratified Screening for Prostate Cancer. Journal of the National Cancer Institute, 2020, 112, 1013-1020. | 3.0 | 23 |
| 54 | Fatherhood status and risk of prostate cancer: Nationwide, populationâ€based caseâ€“control study. International Journal of Cancer, 2013, 133, 937-943. | 2.3 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | It Ainâ€™t What You Do, It's the Way You Do It: Five Golden Rules for Transforming Prostate-Specific Antigen Screening. European Urology, 2014, 66, 188-190. | 0.9 | 21 |
| 56 | The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. Nature Reviews Clinical Oncology, 2016, 13, 394-394. | 12.5 | 21 |
| 57 | Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urology, 2014, 14, 25. | 0.6 | 20 |
| 58 | The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. Journal of Urology, 2016, 195, 1390-1396. | 0.2 | 20 |
| 59 | Personalized risk â€" stratified screening or abandoning it altogether?. Nature Reviews Clinical Oncology, 2016, 13, 140-142. | 12.5 | 20 |
| 60 | Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. Journal of Urology, 2016, 196, 703-708. | 0.2 | 17 |
| 61 | Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e9-637.e15. | 0.8 | 17 |
| 62 | Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scandinavian Journal of Urology and Nephrology, 2009, 43, 350-356. | 1.4 | 16 |
| 63 | Risk of Incisional Hernia after Minimally Invasive and Open Radical Prostatectomy. Journal of Urology, 2013, 190, 1757-1762. | 0.2 | 16 |
| 64 | Active surveillance for prostate cancer. Translational Andrology and Urology, 2021, 10, 2809-2819. | 0.6 | 16 |
| 65 | The absence of voiding symptoms in men with a prostateâ€specific antigen (PSA) concentration of â‰¥3.0â€ƒng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU International, 2012, 110, 638-643. | 1.3 | 15 |
| 66 | A Different Method of Evaluation of the ERSPC Trial Confirms That Prostate-specific Antigen Testing Has a Significant Impact on Prostate Cancer Mortality. European Urology, 2014, 66, 401-403. | 0.9 | 14 |
| 67 | Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e9-151.e15. | 0.8 | 13 |
| 68 | Prostate cancer screeningâ€"when to start and how to screen?. Translational Andrology and Urology, 2018, 7, 34-45. | 0.6 | 13 |
| 69 | Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute, 2022, 114, 1012-1019. | 3.0 | 13 |
| 70 | Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. European Journal of Cancer, 2013, 49, 3041-3048. | 1.3 | 12 |
| 71 | Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. Journal of Urology, 2021, 205, 1055-1062. | 0.2 | 12 |
| 72 | Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. Radiology, 2022, 302, 595-602. | 3.6 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evidence-Based Medicine, 2011, 16, 20-21. | 0.6 | 11 |
| 74 | Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148. | 2.9 | 11 |
| 75 | Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study. Cancer Causes and Control, 2013, 24, 383-390. | 0.8 | 10 |
| 76 | Can one blood draw replace transrectal ultrasonographyâ€estimated prostate volume to predict prostate cancer risk?. BJU International, 2013, 112, 602-609. | 1.3 | 10 |
| 77 | What's new in screening in 2015?. Current Opinion in Urology, 2016, 26, 447-458. | 0.9 | 10 |
| 78 | Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias?. European Urology, 2015, 68, 183-184. | 0.9 | 9 |
| 79 | Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). BJU International, 2016, 118, 677-680. | 1.3 | 9 |
| 80 | Prostate cancer risk assessment in men with an initial P.S.A. below 3â€‰ng/mL: results from the GÃ¶teborg randomized population-based prostate cancer screening trial. Scandinavian Journal of Urology, 2018, 52, 256-262. | 0.6 | 9 |
| 81 | Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592. | 2.0 | 9 |
| 82 | A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609. | 2.9 | 9 |
| 83 | Sexual and Gender Minority Personsâ€™ Perception of the Female Sexual Function Index. Journal of Sexual Medicine, 2021, 18, 2020-2027. | 0.3 | 8 |
| 84 | Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality. Journal of Medical Screening, 2012, 19, 133-140. | 1.1 | 7 |
| 85 | Spotlight on prostate cancer: the latest evidence and current controversies. BMC Medicine, 2015, 13, 60. | 2.3 | 7 |
| 86 | The USPSTF screening recommendation: a swinging pendulum. Nature Reviews Urology, 2018, 15, 532-534. | 1.9 | 7 |
| 87 | Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. European Urology, 2019, 75, 1015-1022. | 0.9 | 7 |
| 88 | Patient-reported pain, discomfort, and anxiety during magnetic resonance imaging-targeted prostate biopsy. Canadian Urological Association Journal, 2019, 14, E202-E208. | 0.3 | 7 |
| 89 | Perspective on Prostate Cancer Screening. Clinical Chemistry, 2019, 65, 24-27. | 1.5 | 7 |
| 90 | Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. European Urology Open Science, 2020, 20, 54-61. | 0.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Patient accrual and understanding of informed consent in a two-stage consent design. Clinical Trials, 2021, 18, 377-382. | 0.7 | 7 |
| 92 | Clinician perspectives on communication and implementation challenges in precision oncology. Personalized Medicine, 2021, 18, 559-572. | 0.8 | 7 |
| 93 | Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2022, 208, 309-316. | 0.2 | 7 |
| 94 | Letter to the editor concerning â€˜Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysisâ€™. Annals of Oncology, 2015, 26, 1031. | 0.6 | 5 |
| 95 | Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial. Journal of Medical Screening, 2017, 24, 98-103. | 1.1 | 5 |
| 96 | Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic. JCO Clinical Cancer Informatics, 2018, 2, 1-10. | 1.0 | 5 |
| 97 | On Risk Estimation versus Risk Stratification in Early Prostate Cancer. PLoS Medicine, 2016, 13, e1002100. | 3.9 | 5 |
| 98 | The Relationship Between PSA and Total Testosterone Levels in Men with Prostate Cancer. Journal of Sexual Medicine, 2022, 19, 471-478. | 0.3 | 5 |
| 99 | The dilemmas of prostate cancer screening. Medical Journal of Australia, 2013, 198, 528-529. | 0.8 | 4 |
| 100 | RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection. Journal of the National Cancer Institute, 2014, 106, . | 3.0 | 4 |
| 101 | Prostate cancer screening in Europe â€“ Authors' reply. Lancet, The, 2015, 385, 1507-1508. | 6.3 | 4 |
| 102 | Racial Disparities in Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2019, 321, 1726. | 3.8 | 4 |
| 103 | What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiology, 2017, 46, 14-19. | 0.8 | 3 |
| 104 | Reply to â€˜Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice settingâ€™. Prostate Cancer and Prostatic Diseases, 2018, 21, 446-447. | 2.0 | 3 |
| 105 | Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-naive Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study. European Urology, 2019, 76, 534-535. | 0.9 | 3 |
| 106 | Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191. | 1.6 | 3 |
| 107 | Towards Wiser Use and Interpretation of P Values. Journal of Sexual Medicine, 2020, 17, 1-3. | 0.3 | 3 |
| 108 | Asian-American Race and Urinary Continence After Radical Prostatectomy. European Urology Open Science, 2020, 22, 51-53. | 0.2 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Reply to Roderick C.N. van den Bergh, Olivier RouviÃ re, and Theodorus van der Kwastâ€™s Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€“6. Prebiopsy MRI: Through the Looking Glass. European Urology, 2020, 78, 314-315. | 0.9 | 3 |
| 110 | Estimating patient health in prostate cancer treatment counseling. Prostate Cancer and Prostatic Diseases, 2023, 26, 271-275. | 2.0 | 3 |
| 111 | Modeling the outcomes of prostate cancer screening. Nature Reviews Urology, 2012, 9, 183-185. | 1.9 | 2 |
| 112 | Toward Responsible, Informed Decision Making for Prostate Cancer Treatment Decisions. Journal of Clinical Oncology, 2019, 37, 3462-3462. | 0.8 | 2 |
| 113 | Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. European Urology, 2020, 78, 927-929. | 0.9 | 2 |
| 114 | â€œPSA Surveillance in the Septuagenarianâ€: A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older. European Urology, 2020, 78, 136-137. | 0.9 | 2 |
| 115 | Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review. European Urology, 2021, 79, 330-333. | 0.9 | 2 |
| 116 | On manels and manferences in urology. Nature Reviews Urology, 2021, 18, 639-640. | 1.9 | 2 |
| 117 | Shared Medical Appointments for Prostate Cancer Active Surveillance Followup Visits. Urology Practice, 2021, 8, 541-545. | 0.2 | 2 |
| 118 | Long-term predictive value of serum PSA values obtained in clinical practice: Results from the Norwegian Prostate Cancer Consortium (NPCC).. Journal of Clinical Oncology, 2022, 40, 5021-5021. | 0.8 | 2 |
| 119 | PSA: role in screening and monitoring patients with prostate cancer. , 2022, , 131-172. | | 2 |
| 120 | Screening for Prostate Cancer. Annals of Internal Medicine, 2012, 156, 539. | 2.0 | 1 |
| 121 | Fourâ€hundredfold overestimation of biopsy mortality. BJU International, 2013, 111, E16-7. | 1.3 | 1 |
| 122 | Editorial Comment. Journal of Urology, 2016, 196, 1051-1051. | 0.2 | 1 |
| 123 | The ERSPC Study: Quality Takes Time and Perseverance. Clinical Chemistry, 2019, 65, 208-209. | 1.5 | 1 |
| 124 | When to Discuss Prostate Cancer Screening With Average-Risk Men. American Journal of Preventive Medicine, 2021, 61, 294-298. | 1.6 | 1 |
| 125 | Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmÃ¶ preventive project. Oncotarget, 2018, 9, 5778-5785. | 0.8 | 1 |
| 126 | Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. European Urology, 2022, , . | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Introduction to a seminar on revisiting the value of PSA-based prostate cancer screening. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 76-77. | 0.8 | 1 |
| 128 | Response. Journal of the National Cancer Institute, 2014, 106, . | 3.0 | 0 |
| 129 | Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. European Urology Focus, 2015, 1, 149-151. | 1.6 | 0 |
| 130 | Editorial Comment. Journal of Urology, 2017, 198, 57-57. | 0.2 | 0 |
| 131 | Editorial Comment. Journal of Urology, 2018, 200, 87-87. | 0.2 | 0 |
| 132 | Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duanâ€™s Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€“6. European Urology, 2021, 79, e16. | 0.9 | 0 |
| 133 | What is a good medical choice?. Cancer, 2021, 127, 1933-1934. | 2.0 | 0 |
| 134 | Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973. | 1.1 | 0 |
| 135 | The dilemmas of prostate cancer screening. Medical Journal of Australia, 2013, 199, 583-584. | 0.8 | 0 |
| 136 | Reply by Authors. Journal of Urology, 2020, 203, 1121-1121. | 0.2 | 0 |
| 137 | Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study. Scandinavian Journal of Urology, 2022, 56, 182-190. | 0.6 | 0 |